In Lexington, the firm completes the new headquarters for Translate Bio, an RNA therapeutics company on the leading edge of the next wave of pharmaceutical innovation. The architecture supports a level of computational and laboratory precision that previous generations of biotech could not have anticipated. RNA work like this will, within a few years, become the foundation of pandemic-era vaccines.